In addition to AKI, NGAL can be used to predict adverse outcomes in the medium term, since its early measurement in the context of critical situations disease can identify patients with AKI at increased risk of death or progression to CKD in the following nine months [8]. Here, LCN2 is linked to chronic kidney disease.